[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Invacare Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":101},{"warningLetters":4,"total":100},[5,33,58,80],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},3009,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-11-30T14:20:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-18T05:00:00Z\">11\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvacare-corporation-617319-11182021\">Invacare Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvacare-corporation-617319-08212023\">\u003Ctime datetime=\"2023-08-24T04:00:00Z\">08\u002F24\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Matthew E. Monaghan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman, President\u002FChief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Invacare Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>One Invacare Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elyria\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44035\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mmonaghan@invacare.com\"> mmonaghan@invacare.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 617319\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 18, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Monaghan:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 1200 Taylor Street (FEI: 1525712), One Invacare Way (FEI: 3002889431), and 39400 Taylor Parkway (FEI: 1000220413), from May 25, 2021 to June 24, 2021. During the inspection, FDA investigators determined that your firm is a manufacturer of a variety of Class II Oxygen Concentrators intended for patients with respiratory disorders requiring supplemental oxygen. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 from Jason Fiest, Vice President Quality and Regulatory North America, concerning our investigators’ observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on June 24, 2021. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 C.F.R. § 820.198(c).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not conduct an investigation of complaints when a device, including your oxygen concentrators, is either past the device end of life (EOL) or component wear period as defined in “Expiration of Consumables and End of Life for Devices” (RD-CP14-002-023a; Rev. C; Effective: 2\u002F4\u002F20) unless the device is associated with an alleged malfunction found to cause or contribute to an injury, illness, or death or the complaint contains a pre-defined key word as defined in “Complaint Evaluation, Investigation and Reporting” (WI-CP14-002-023; Rev. G, J; Effective: 4\u002F11\u002F19, 6\u002F30\u002F20). Moreover, your firm does not investigate complaints if a component was alleged to be the cause of the failure or if there was an assumption that any component failure was based on wear. For example, from February 1, 2020 to April 30, 2021, your firm did not investigate approximately 10% of your Oxygen Concentrator complaints (2,589\u002F25,777) despite these complaints involving the possible failure of a device to meet its specifications.\u003C\u002Fp>\n\n\u003Cp>The responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 are inadequate. According to your responses, CAPA CA-00067 was opened on June 25, 2021. The root cause analysis and procedural update to \u003Cstrong>(b)(4)\u003C\u002Fstrong> related to device end of life and component wear period followed by training have been completed. However, your procedure still does not require investigations of complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications (regardless of whether it was found to cause or contribute to an injury\u002Fillness or death).\u003C\u002Fp>\n\n\u003Cp>Additional completed corrective actions included \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the EOL and wear reference guide. In addition, your firm completed the temporary protocol for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> review of complaint records which were not investigated based on EOL or component wear period. Planned actions include \u003Cstrong>(b)(4)\u003C\u002Fstrong> review of complaint records. Please provide an update on the corrective actions.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 C.F.R. § 820.198(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s procedure titled “Customer Feedback and Complaint Entry” (WI-CP14-002-022; Rev.G; Effective: 12\u002F1\u002F20) which requires a device return for further investigation when the complaint contains the key word of injury, illness, or death with a harm and is assigned a severity score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a given harm as defined in the “Harms and Severity Table Guidelines” (#RD-CP07-001b; Rev.F; Effective: 12\u002F20\u002F19) is inadequate. Harms such as allergic reaction, chemical burns, hypoxia, and hypercapnia are given a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the “Harms and Severity Table Guidelines” although the potential for severity of harms may be higher. For example, you received a complaint which alleged a user had to be taken to the hospital via ambulance to receive oxygen because your Platinum 10 Oxygen Concentrator was not producing the proper amount of oxygen (Complaint 263736). The alleged harm of hypoxia was assigned a severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as defined in the “Harms and Severity Table Guidelines” and the unit was not requested for return for further investigation.\u003C\u002Fp>\n\n\u003Cp>The responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 are inadequate. The immediate correction to justify the assigned severity score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for hypoxia in Complaint 263736, because your device labeling instructs the user to have a backup supply in case the device malfunctions is inadequate, since the user had to be given oxygen at the hospital to preclude permanent impairment of a body function or structure or possibly death.\u003C\u002Fp>\n\n\u003Cp>According to your responses, CAPA CA-00068 was opened on June 25, 2021. A root cause analysis was completed as well as a review of randomly selected complaints which concluded harms and severity scores were accurately applied, updates to procedures, training and justification of the severity scores in the “Harms and Severity Table Guidelines” procedure. Please provide an update on these corrective actions and your plan to address the inadequacy of your justification for assignment of a severity score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Complaint 263736.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain adequate procedures for implementing corrective and preventive action that shall include requirements for using appropriate statistical methodology where necessary to detect recurring quality problems as required by 21 C.F.R. § 820.100(a)(1).\u003C\u002Fp>\n\n\u003Cp>(a) Specifically, your firm’s procedure titled “Analysis Of Customer Complaints” (WI-HQ17-002-001; Rev.N; Effective: 8\u002F6\u002F19) for statistical analysis of complaints or any other such procedure does not require further analysis of complaints designated with an alleged symptom of “other” to determine if another category should be created or if a corrective action is warranted for any recurring issues despite the prevalence of such complaints in the top 6 alleged symptoms for Oxygen Concentrators in the 2020 Quarter 4 complaint analysis report.\u003C\u002Fp>\n\n\u003Cp>The responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 are inadequate. According to your responses, CAPA CA-00070 was opened on June 25, 2021. The root cause analysis and procedural update to include analysis of complaints with an alleged symptom of “other” has been completed. However, the procedural update does not clearly explain how the “other” alleged symptom codes will be analyzed or how trending activities based on the “other” alleged symptom codes will be incorporated into the complaint process.\u003C\u002Fp>\n\n\u003Cp>Completed corrective actions included \u003Cstrong>(b)(4)\u003C\u002Fstrong> review on complaints with the “other” category to determine if new alleged symptom codes are appropriate (with reclassification as necessary) and recalculation of baselines based on updated complaint data from reclassified alleged symptom codes. Planned actions include \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities based on updated alleged symptom code baselines to determine if the updated data results in any new triggers; the addition of new alleged symptom codes to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaint database; a procedural update to remove instructions to exclude the alleged symptom code of “other” from special cause trending; and training on updated procedures. Please provide an update on these corrective actions.\u003C\u002Fp>\n\n\u003Cp>(b) Specifically, your firm does not analyze component failures for supplier monitoring although such information is captured in complaints where component(s) were found to be an underlying contributor. For example, from February 1, 2020 to April 30, 2021, approximately 81% (20,760\u002F25,777) of complaints for the oxygen concentrators were linked to a component as the underlying cause.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 cannot be assessed at this time. According to your responses, CAPA CA-00070 was opened on June 25, 2021 and a root cause analysis has been performed. Completed corrective actions included \u003Cstrong>(b)(4)\u003C\u002Fstrong> review of complaint data to determine the appropriate method for using the available component underlying cause data and the creation of a template to use for trending complaints by component underlying cause. Planned actions include validation of the component underlying cause template; establishment of baselines for trending by component; retrospective trending by component underlying cause; and procedural updates, followed up with training. Please provide an update on these corrective actions.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for implementing corrective and preventive actions as required by 21 C.F.R. § 820.100(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your corrective\u002Fpreventive actions activities documented under CAPA #00046, regarding your Class II Recall Z-0514-2021 (initiated 9\u002F14\u002F20) for Perfecto Oxygen concentrators were inadequate. For example, one of the root causes was documented as a “poorly defined specification”. You did not investigate further to determine what part of your quality system allowed for this to occur and no corrective actions were implemented to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 cannot be assessed at this time. According to your responses, CAPA CA-00069 was opened on June 25, 2021 to address the inadequacy of the CAPA procedure which allowed CAPA CA-00046 to be completed without identifying a quality system root cause. Also, CAPA CA-00073 was opened on July 1, 2021 to determine the systemic root cause of CAPA CA-00046. Completed corrective actions for CAPA CA-00069 included root cause analysis; \u003Cstrong>(b)(4)\u003C\u002Fstrong> review of corrective and preventive actions (CAPA) records; and procedural updates followed up with training. Completed corrective actions for CAPA CA-00073 included root cause analysis; updates to Failure Modes and Effects Analysis procedure and risk management plans with consideration of life requirements; and revision of the print review form on when supplier risk documentation should be obtained. Planned actions for CAPA CA-00073 include training on updated procedures and identification of appropriate product-specific training requirements for oxygen systems. Please provide an update on these corrective actions.\u003C\u002Fp>\n\n\u003Cp>5. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 C.F.R. § 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints COMP-264183, COMP-265814, COMP-266384, COMP-266537, COMP-269058, COMP-270152, COMP-271453, COMP-277126, COMP-277205, COMP-278575, COMP-279342, COMP-279333 and COMP-280777 reasonably suggests that your firm’s oxygen concentrator malfunctioned (e.g. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) while in use. The same malfunction is the subject of the recall Z-0514-2021 for the same device. Per the 1995 Preamble, a malfunction is reportable if the manufacturer takes, or would be required to take, an action under section 518 or 519(g) of the FD&amp;C as a result of the malfunction of the device or other similar devices. (Refer to 1995 Federal Register Volume 60, Number 237, Page 63585. Please note that the preamble reference is section 519(f), but the appropriate designation for the section is now section 519(g) due to amendments to the FD&amp;C Act). There is no information included for the complaint files that justifies that the malfunction would not be likely to cause or contribute to a death or serious injury, if it were to recur. As such, your firm should have submitted 13 MDRs, corresponding to each MDR reportable event reference in the complaints. However, your firm failed to submit an MDR to FDA for each reportable event referenced in the complaints.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated July 16, 2021 cannot be determined at this time. The response noted that it will perform its retrospective review of complaints from November 13, 2020 through July 31, 2021 and staff training. We acknowledged that thirteen complaints referenced above were submitted as initial reports. However, your firm did not provide documentation or evidence that all the planned corrections and corrective actions, including the planned retrospective review and assessment of its reportability criteria, have been implemented and completed as they are still in progress.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated August 31, 2021 cannot be determined at this time. The response noted that it completed its retrospective review, submitted MDRs for the reportable events received and updated its reportability criteria. However, your firm did not provide documentation or evidence that effectiveness check of corrections and corrective actions have been completed as it is still in progress. Furthermore, please provide an update on these corrective actions and justification for why a retrospective review of complaints for similar devices (not attributed to CAPA CA-00046) would not be required to determine if this malfunction is systemic in nature.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated September 30, 2021 appears to be adequate. In the response, your firm provided evidence that it completed all the corrections and corrective actions, including effectiveness check.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003Cbr>\n\u003Cbr>\nAdditionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer, Sargum C. Morgan at 313-409-7331 or at sargum.morgan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision I\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMatthew E. Monaghan\n\nRecipient Title\n\nChairman, President\u002FChief Executive Officer\n\nInvacare Corporation\n\nOne Invacare Way\n\nElyria, OH 44035\n\nUnited States\n\nmmonaghan@invacare.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 617319\n\nNovember 18, 2021\n\nDear Mr. Monaghan:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 1200 Taylor Street (FEI: 1525712), One Invacare Way (FEI: 3002889431), and 39400 Taylor Parkway (FEI: 1000220413), from May 25, 2021 to June 24, 2021. During the inspection, FDA investigators determined that your firm is a manufacturer of a variety of Class II Oxygen Concentrators intended for patients with respiratory disorders requiring supplemental oxygen. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 from Jason Fiest, Vice President Quality and Regulatory North America, concerning our investigators’ observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on June 24, 2021. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 C.F.R. § 820.198(c).\n\nSpecifically, your firm does not conduct an investigation of complaints when a device, including your oxygen concentrators, is either past the device end of life (EOL) or component wear period as defined in “Expiration of Consumables and End of Life for Devices” (RD-CP14-002-023a; Rev. C; Effective: 2\u002F4\u002F20) unless the device is associated with an alleged malfunction found to cause or contribute to an injury, illness, or death or the complaint contains a pre-defined key word as defined in “Complaint Evaluation, Investigation and Reporting” (WI-CP14-002-023; Rev. G, J; Effective: 4\u002F11\u002F19, 6\u002F30\u002F20). Moreover, your firm does not investigate complaints if a component was alleged to be the cause of the failure or if there was an assumption that any component failure was based on wear. For example, from February 1, 2020 to April 30, 2021, your firm did not investigate approximately 10% of your Oxygen Concentrator complaints (2,589\u002F25,777) despite these complaints involving the possible failure of a device to meet its specifications.\n\nThe responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 are inadequate. According to your responses, CAPA CA-00067 was opened on June 25, 2021. The root cause analysis and procedural update to (b)(4) related to device end of life and component wear period followed by training have been completed. However, your procedure still does not require investigations of complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications (regardless of whether it was found to cause or contribute to an injury\u002Fillness or death).\n\nAdditional completed corrective actions included (b)(4) of the EOL and wear reference guide. In addition, your firm completed the temporary protocol for the (b)(4) review of complaint records which were not investigated based on EOL or component wear period. Planned actions include (b)(4) review of complaint records. Please provide an update on the corrective actions.\n\n2. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 C.F.R. § 820.198(a).\n\nSpecifically, your firm’s procedure titled “Customer Feedback and Complaint Entry” (WI-CP14-002-022; Rev.G; Effective: 12\u002F1\u002F20) which requires a device return for further investigation when the complaint contains the key word of injury, illness, or death with a harm and is assigned a severity score of (b)(4) for a given harm as defined in the “Harms and Severity Table Guidelines” (#RD-CP07-001b; Rev.F; Effective: 12\u002F20\u002F19) is inadequate. Harms such as allergic reaction, chemical burns, hypoxia, and hypercapnia are given a score of (b)(4) in the “Harms and Severity Table Guidelines” although the potential for severity of harms may be higher. For example, you received a complaint which alleged a user had to be taken to the hospital via ambulance to receive oxygen because your Platinum 10 Oxygen Concentrator was not producing the proper amount of oxygen (Complaint 263736). The alleged harm of hypoxia was assigned a severity of (b)(4) as defined in the “Harms and Severity Table Guidelines” and the unit was not requested for return for further investigation.\n\nThe responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 are inadequate. The immediate correction to justify the assigned severity score of (b)(4) for hypoxia in Complaint 263736, because your device labeling instructs the user to have a backup supply in case the device malfunctions is inadequate, since the user had to be given oxygen at the hospital to preclude permanent impairment of a body function or structure or possibly death.\n\nAccording to your responses, CAPA CA-00068 was opened on June 25, 2021. A root cause analysis was completed as well as a review of randomly selected complaints which concluded harms and severity scores were accurately applied, updates to procedures, training and justification of the severity scores in the “Harms and Severity Table Guidelines” procedure. Please provide an update on these corrective actions and your plan to address the inadequacy of your justification for assignment of a severity score of (b)(4) for Complaint 263736.\n\n3. Failure to establish and maintain adequate procedures for implementing corrective and preventive action that shall include requirements for using appropriate statistical methodology where necessary to detect recurring quality problems as required by 21 C.F.R. § 820.100(a)(1).\n\n(a) Specifically, your firm’s procedure titled “Analysis Of Customer Complaints” (WI-HQ17-002-001; Rev.N; Effective: 8\u002F6\u002F19) for statistical analysis of complaints or any other such procedure does not require further analysis of complaints designated with an alleged symptom of “other” to determine if another category should be created or if a corrective action is warranted for any recurring issues despite the prevalence of such complaints in the top 6 alleged symptoms for Oxygen Concentrators in the 2020 Quarter 4 complaint analysis report.\n\nThe responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 are inadequate. According to your responses, CAPA CA-00070 was opened on June 25, 2021. The root cause analysis and procedural update to include analysis of complaints with an alleged symptom of “other” has been completed. However, the procedural update does not clearly explain how the “other” alleged symptom codes will be analyzed or how trending activities based on the “other” alleged symptom codes will be incorporated into the complaint process.\n\nCompleted corrective actions included (b)(4) review on complaints with the “other” category to determine if new alleged symptom codes are appropriate (with reclassification as necessary) and recalculation of baselines based on updated complaint data from reclassified alleged symptom codes. Planned actions include (b)(4) activities based on updated alleged symptom code baselines to determine if the updated data results in any new triggers; the addition of new alleged symptom codes to the (b)(4) complaint database; a procedural update to remove instructions to exclude the alleged symptom code of “other” from special cause trending; and training on updated procedures. Please provide an update on these corrective actions.\n\n(b) Specifically, your firm does not analyze component failures for supplier monitoring although such information is captured in complaints where component(s) were found to be an underlying contributor. For example, from February 1, 2020 to April 30, 2021, approximately 81% (20,760\u002F25,777) of complaints for the oxygen concentrators were linked to a component as the underlying cause.\n\nThe adequacy of your responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 cannot be assessed at this time. According to your responses, CAPA CA-00070 was opened on June 25, 2021 and a root cause analysis has been performed. Completed corrective actions included (b)(4) review of complaint data to determine the appropriate method for using the available component underlying cause data and the creation of a template to use for trending complaints by component underlying cause. Planned actions include validation of the component underlying cause template; establishment of baselines for trending by component; retrospective trending by component underlying cause; and procedural updates, followed up with training. Please provide an update on these corrective actions.\n\n4. Failure to establish and maintain procedures for implementing corrective and preventive actions as required by 21 C.F.R. § 820.100(a).\n\nSpecifically, your corrective\u002Fpreventive actions activities documented under CAPA #00046, regarding your Class II Recall Z-0514-2021 (initiated 9\u002F14\u002F20) for Perfecto Oxygen concentrators were inadequate. For example, one of the root causes was documented as a “poorly defined specification”. You did not investigate further to determine what part of your quality system allowed for this to occur and no corrective actions were implemented to prevent recurrence.\n\nThe adequacy of your responses dated July 16, 2021, August 31, 2021, September 30, 2021, and October 29, 2021 cannot be assessed at this time. According to your responses, CAPA CA-00069 was opened on June 25, 2021 to address the inadequacy of the CAPA procedure which allowed CAPA CA-00046 to be completed without identifying a quality system root cause. Also, CAPA CA-00073 was opened on July 1, 2021 to determine the systemic root cause of CAPA CA-00046. Completed corrective actions for CAPA CA-00069 included root cause analysis; (b)(4) review of corrective and preventive actions (CAPA) records; and procedural updates followed up with training. Completed corrective actions for CAPA CA-00073 included root cause analysis; updates to Failure Modes and Effects Analysis procedure and risk management plans with consideration of life requirements; and revision of the print review form on when supplier risk documentation should be obtained. Planned actions for CAPA CA-00073 include training on updated procedures and identification of appropriate product-specific training requirements for oxygen systems. Please provide an update on these corrective actions.\n\n5. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 C.F.R. § 803.50(a)(2).\n\nFor example, the information included for Complaints COMP-264183, COMP-265814, COMP-266384, COMP-266537, COMP-269058, COMP-270152, COMP-271453, COMP-277126, COMP-277205, COMP-278575, COMP-279342, COMP-279333 and COMP-280777 reasonably suggests that your firm’s oxygen concentrator malfunctioned (e.g. (b)(4)) while in use. The same malfunction is the subject of the recall Z-0514-2021 for the same device. Per the 1995 Preamble, a malfunction is reportable if the manufacturer takes, or would be required to take, an action under section 518 or 519(g) of the FD&C as a result of the malfunction of the device or other similar devices. (Refer to 1995 Federal Register Volume 60, Number 237, Page 63585. Please note that the preamble reference is section 519(f), but the appropriate designation for the section is now section 519(g) due to amendments to the FD&C Act). There is no information included for the complaint files that justifies that the malfunction would not be likely to cause or contribute to a death or serious injury, if it were to recur. As such, your firm should have submitted 13 MDRs, corresponding to each MDR reportable event reference in the complaints. However, your firm failed to submit an MDR to FDA for each reportable event referenced in the complaints.\n\nThe adequacy of your firm’s response dated July 16, 2021 cannot be determined at this time. The response noted that it will perform its retrospective review of complaints from November 13, 2020 through July 31, 2021 and staff training. We acknowledged that thirteen complaints referenced above were submitted as initial reports. However, your firm did not provide documentation or evidence that all the planned corrections and corrective actions, including the planned retrospective review and assessment of its reportability criteria, have been implemented and completed as they are still in progress.\n\nThe adequacy of your firm’s response dated August 31, 2021 cannot be determined at this time. The response noted that it completed its retrospective review, submitted MDRs for the reportable events received and updated its reportability criteria. However, your firm did not provide documentation or evidence that effectiveness check of corrections and corrective actions have been completed as it is still in progress. Furthermore, please provide an update on these corrective actions and justification for why a retrospective review of complaints for similar devices (not attributed to CAPA CA-00046) would not be required to determine if this malfunction is systemic in nature.\n\nYour firm’s response dated September 30, 2021 appears to be adequate. In the response, your firm provided evidence that it completed all the corrections and corrective actions, including effectiveness check.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nAdditionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer, Sargum C. Morgan at 313-409-7331 or at sargum.morgan@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision I\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Invacare Corporation","invacare-corporation-617319-11182021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvacare-corporation-617319-11182021","2026-10-26T08:09:00.313959+00:00","Warning Letter","Closed Out","2021-11-30","617319","Medical Devices","2023-08-24","Matthew E. Monaghan","2026-08-20T02:22:40.989+00:00","United Parcel Service","2021-11-18",{"id":34,"raw":35,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":39,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":56,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},697,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-15T04:00:00Z\">08\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnate-healthcare-institute-695592-08152025\">Innate Healthcare Institute\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-695592\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Travis Whitney, NMD, DAASCP, MSc, MSAc \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Chief Medical Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Innate Healthcare Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4835 East Cactus Road, Suite 140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85254\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@innatehealthcare.org\"> info@innatehealthcare.org \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 15, 202\u003C\u002Fp>\u003Cp>CBER 25-695592\u003C\u002Fp>\u003Cp>Dear Dr. Whitney:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Finnatehealthcare.org (last visited August 2025), through which your company markets “umbilical cord mesenchymal stem cells (UC-MSCs),” which you also describe as “UC-MSC therapy” (hereinafter, “your product”) for allogeneic use. This letter is to advise you that your misbranding of your product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, https:\u002F\u002Finnatehealthcare.org (last visited August 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,&nbsp;\u003C\u002Fp>\u003Cp>On your website, https:\u002F\u002Finnatehealthcare.org, you provide the following statements:\u003C\u002Fp>\u003Cul>\u003Cli>“At Innate Healthcare Institute, we combine an effective blend of integrative medicine and regenerative stem cell medicine, treating Autism at its root.”\u003C\u002Fli>\u003Cli>“Stem cell therapy has really helped our son with his autism”\u003C\u002Fli>\u003Cli>“Stem cell therapy with human umbilical cord tissue derived mesenchymal stem cells (UC-MSCs) corrects the inflammatory process by modulating the immune system from a pro-inflammatory attacking state to an anti-inflammatory healthy state. They also have the ability to regenerate damage done from the autoimmune attack. Stem cells do this by secreting healing activators such as growth factors, cytokines, and exosomes to the surrounding environment.”\u003C\u002Fli>\u003Cli>“Stem cell therapy for autism can lead to improvement in cognitive ability, behaviors, and sociability.”\u003C\u002Fli>\u003Cli>“Regenerative cell medicine has the potential to help with many conditions such as pain due to osteoarthritis, tendinopathy\u002Ftendonitis, degenerative disc disease, herniated discs, neuropathy, fractures, muscle injuries, ligament and tendon injuries, COPD, peripheral neuropathy, sexual dysfunction, autoimmune conditions, heart disease, and many more.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your UC-MSCs product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Innate Healthcare Institute does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>For example, your UC-MSCs product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your UC-MSCs product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your product is intended for use in the treatment of autism as well as other diseases or conditions, which is not a basic function of the umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>Furthermore, your product is a misbranded drug under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). Misbranding your product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act and biological products under section 351 of the PHS Act and and are subject to premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>CC:\u003C\u002Fp>\u003Cp>Innate Healthcare, LLC\u003Cbr>4840 East Indian School Road\u003Cbr>Suite 104\u003Cbr>Phoenix, AZ 85018\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-695592\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nTravis Whitney, NMD, DAASCP, MSc, MSAc\n\nRecipient Title\n\nFounder and Chief Medical Officer\n\nInnate Healthcare Institute\n\n4835 East Cactus Road, Suite 140\n\nScottsdale, AZ 85254\n\nUnited States\n\ninfo@innatehealthcare.org\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nAugust 15, 202\nCBER 25-695592\nDear Dr. Whitney:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Finnatehealthcare.org (last visited August 2025), through which your company markets “umbilical cord mesenchymal stem cells (UC-MSCs),” which you also describe as “UC-MSC therapy” (hereinafter, “your product”) for allogeneic use. This letter is to advise you that your misbranding of your product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k).\nViolations\nBased on information and records reviewed by FDA, https:\u002F\u002Finnatehealthcare.org (last visited August 2025), your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nOn your website, https:\u002F\u002Finnatehealthcare.org, you provide the following statements:\n“At Innate Healthcare Institute, we combine an effective blend of integrative medicine and regenerative stem cell medicine, treating Autism at its root.”\n“Stem cell therapy has really helped our son with his autism”\n“Stem cell therapy with human umbilical cord tissue derived mesenchymal stem cells (UC-MSCs) corrects the inflammatory process by modulating the immune system from a pro-inflammatory attacking state to an anti-inflammatory healthy state. They also have the ability to regenerate damage done from the autoimmune attack. Stem cells do this by secreting healing activators such as growth factors, cytokines, and exosomes to the surrounding environment.”\n“Stem cell therapy for autism can lead to improvement in cognitive ability, behaviors, and sociability.”\n“Regenerative cell medicine has the potential to help with many conditions such as pain due to osteoarthritis, tendinopathy\u002Ftendonitis, degenerative disc disease, herniated discs, neuropathy, fractures, muscle injuries, ligament and tendon injuries, COPD, peripheral neuropathy, sexual dysfunction, autoimmune conditions, heart disease, and many more.”\nTherefore, your product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour UC-MSCs product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Innate Healthcare Institute does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your UC-MSCs product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your UC-MSCs product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your product is intended for use in the treatment of autism as well as other diseases or conditions, which is not a basic function of the umbilical cord in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\nFurthermore, your product is a misbranded drug under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). Misbranding your product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nAdditional Concerns\nFDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are regulated as drugs as defined in section 201(g)(1) of the FD&C Act and biological products under section 351 of the PHS Act and and are subject to premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCC:\nInnate Healthcare, LLC\n4840 East Indian School Road\nSuite 104\nPhoenix, AZ 85018\n____________________\n1 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Innate Healthcare Institute","innate-healthcare-institute-695592-08152025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finnate-healthcare-institute-695592-08152025","2026-10-26T08:08:58.9915+00:00","Issued","2025-08-26","695592","Biologics","Travis Whitney, NMD, DAASCP, MSc, MSAc","2026-08-19T16:28:46.246+00:00","VIA UPS and Electronic Mail","CBER 25-695592","2025-08-15",{"id":59,"raw":60,"subject":65,"body_html":66,"body_text":67,"firm_name":68,"letter_id":69,"created_at":70,"fei_number":20,"letter_url":71,"updated_at":72,"action_type":23,"case_status":49,"posted_date":73,"marcs_cms_no":74,"product_type":75,"closeout_date":20,"issuing_office":64,"recipient_name":76,"body_fetched_at":77,"delivery_method":78,"recipient_title":20,"reference_number":20,"action_taken_date":79,"medical_device_id":20,"response_letter_date":20},1526,[61,62,63,64,65,13,13,13],"\u003Ctime datetime=\"2024-04-09T13:20:00Z\">04\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-28T04:00:00Z\">03\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkilitch-healthcare-india-limited-672956-03282024\">Kilitch Healthcare India Limited\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paresh Mehta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kilitch Healthcare India Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>902-B, Godrej Coliseum, Behind Everard Nagar\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Off. Eastern Express Highway, Nr. Priyadarshani Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sion (E.), Mumbai\u003C\u002Fspan> \u003Cspan>400022\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-29\u003C\u002Fp>\n\n\u003Cp>March 28, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Mehta:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kilitch Healthcare India Limited, FEI 3011853060, at R - 904 905 T T C Industrial Road,\u003Cbr>\nNavi Mumbai from October 12 to October 20, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Because your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 10, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Insanitary Conditions\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your drug products are adulterated under section 501(a)(2)(A) of the FD&amp;C Act because they were prepared, packed, or held under insanitary conditions. FDA investigators observed your facility to be in a state of disrepair, poorly cleaned and maintained as evidenced by:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> residue on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjacent to the HEPA filters in the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>Multiple barefoot employees in an ISO 8 area, without required gowning, including gloves, while handling materials being transferred into the ISO 7 manufacturing area.\u003C\u002Fli>\n\t\u003Cli>Operators used visibly dirty restricted access barrier system (RABS) \u003Cstrong>(b)(4)\u003C\u002Fstrong> for interventions on the filling line.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is not adequate. While you commit to replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> that surround the HEPA filtration system, your response does not include an evaluation of the residue on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its identity or investigate the source. You also commit to perform re-training of personnel for gowning requirements and implement a procedure for sterilization of RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however, you do not evaluate the microbiological impact that lack of proper gowning and unclean RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> has on your classified areas, such as ISO 5, ISO 7, and ISO 8. The potential impact to sterile drug products produced under these insanitary conditions is also not addressed.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Poor Practices in the Aseptic Processing Areas\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition to the insanitary conditions described above, during the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile drug products. These poor practices included, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Operators performing interventions on the filling line in ISO 5 areas using a cloth to wipe the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the filling \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the conveyor.\u003C\u002Fli>\n\t\u003Cli>Operators leaning over the filling line, including open and filled eye drop bottles, blocking unidirectional airflow.\u003C\u002Fli>\n\t\u003Cli>Operators in the ISO 5 area not wearing goggles and therefore had exposed skin during line set-up and aseptic processing.\u003C\u002Fli>\n\t\u003Cli>Operators observed placing bags of components that made contact with the walls in the ISO 7 area into the ISO 5 area without the bags being disinfected.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate because it does not address the lack of oversight for the operators’ aseptic behaviors and if the initial training received was sufficient. Further, these poor aseptic practices were not investigated to determine the impact to sterile drug products and aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Media Fill Program\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your media fills failed to accurately simulate commercial operations. Our inspection found the aseptic operations simulated during your media fills were not sufficiently representative of commercial aseptic manufacturing operations. It is your routine practice not to document interventions of the filling line in the manufacturing batch record during production. Because of this, your program lacks reliable data to determine the quantity and duration of interventions to simulate during media fills. In addition, during the inspection there were numerous interventions performed during routine manufacturing that were either not simulated as part of a media fill, or lacking in quantity and duration in the media fills compared to what was observed during production.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. While you commit to document routine interventions during manufacturing, you fail to evaluate the interventions used in your media fill program and whether they represent routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity and duration of process simulation interventions should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and sterility assurance cannot be accurately assessed.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Smoke studies performed by your firm are not adequate to show unidirectional airflow in the aseptic processing areas. Multiple instances of turbulent airflow in critical areas of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line were noted, including above the filling \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, smoke study videos did not include set-up of the aseptic processing line or interventions of the filling line that simulate actual manufacturing.\u003C\u002Fp>\n\n\u003Cp>In your response you commit to repeat smoke studies with defined set-up and interventions. This is not adequate as you do not provide details such as who is performing and evaluating the smoke studies, how you will determine what interventions are included, and how you will address potential deficiencies.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and suitability, including ergonomics for each human interaction.\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>\n&nbsp; &nbsp; o Reduction or elimination of aseptic manipulations and connections (e.g., replacing \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic connections with \u003Cstrong>(b)(4)\u003C\u002Fstrong> system)\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>A plan to implement systemic remediations that address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to collect the required amount of environmental and personnel monitoring samples required by your procedures to support the manufacture of sterile drug products. During the inspection, a reconciliation of samples that should have been taken during manufacturing activities and those that were actually taken did not match. Interviews with microbiology laboratory staff and management confirmed that it is your routine practice to fabricate results for samples that were never taken or to alter results for samples that would otherwise fail to meet established specifications.\u003C\u002Fp>\n\n\u003Cp>Batch record information for environmental monitoring (EM) is not recorded at the time of completion. For example, a batch record was being filled out in the microbiology laboratory on October 12, 2023, for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was manufactured in March 2023, approximately six months prior to the recorded date. Data for the microbiological activity in the filtration\u002Ffilling area in the batch record was blank on October 12, 2023. This includes the air sample and non-viable particulate counting start and end times, activity done by signatures and dates, and the checked by signatures and dates. When the record was later provided on October 19, 2023, the record was filled out with times, signatures, and dates in March 2023.\u003C\u002Fp>\n\n\u003Cp>During our inspection, investigators observed multiple sample collections in the ISO 5 and ISO 7 areas, and on personnel that resulted in plate readings with numerous colony forming units (CFUs). Your firm stated that prior to the start of the inspection, where you admitted routine fabrication of environmental monitoring results, no single action limit excursion had been documented, however, FDA investigators observed the following during the inspection:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>15 action level excursions for ISO 5 area environmental monitoring samples\u003C\u002Fli>\n\t\u003Cli>13 action level excursions for personnel monitoring samples\u003C\u002Fli>\n\t\u003Cli>5 action level excursions for ISO 7 area environmental monitoring samples\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Laboratory technicians falsified this data which is critical to maintaining an ongoing state of control in your aseptic processing facility. Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>Your response states that a new checklist and procedure for oversight will be implemented. This response is not adequate as it does not address the data integrity issues that were identified by FDA. In addition, your response does not include a holistic review of data recording practices at your facility. Further, your corrective action and preventive action (CAPA) of adding a laboratory quality unit (QU) checklist for microbiologist tasks is not adequate to ensure contemporaneous completion of laboratory records.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document\u003Cbr>\n\u003Cbr>\n\u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; &nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; &nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; &nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; &nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; &nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; &nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; &nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Environmental Monitoring Deficiencies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your environmental monitoring (EM) program is deficient. Locations selected for EM in critical areas such as the ISO 5 aseptic processing line, do not have scientific justification to support the chosen locations. For example, standard operating procedure (SOP) KHIL\u002FRB\u002FQC\u002F036 “Swab Testing” describes locations such as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” without providing details to ensure samples are taken from the same location each time. When asked to provide justification for sampling locations, no documentation was provided.\u003C\u002Fp>\n\n\u003Cp>Additionally, the materials used to perform environmental and personnel monitoring are inadequate. The media used does not contain a neutralizing agent and operators were observed spraying \u003Cstrong>(b)(4)\u003C\u002Fstrong> near open plates. The plates themselves were observed numerous times to have desiccated media pulling away from the sides of the plates and cracking.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate as you do not include a risk based, scientific study to determine sampling locations for your environmental monitoring. In addition, you failed to evaluate how the growth media and plate deficiencies potentially impact your drug products and facility’s state of control for microbial contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Facility Maintenance Deficiencies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>During the inspection, numerous instances of your facility being in a state of disrepair or unclean were noted. This includes but is not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> surrounding the HEPA filters in the ISO 5 area were detached, creating gaps where air from the ISO 7 area could flow into the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>Hose connected to a leaking purified water use point was submerged in a bucket of stagnant water.\u003C\u002Fli>\n\t\u003Cli>Peeling paint, stains, and residue on the ceiling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate as you failed to consider that persistently deficient environmental controls (e.g., poor design of processing lines, lack of data integrity, and insufficient environmental monitoring) provide a fundamental lack of meaningful retrospective data to support sterility assurance.\u003Cbr>\n\u003Cbr>\nA vigilant ongoing EM program, and supporting laboratory, are essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling frequencies, investigating deviations, and trend analysis. Also ensure the implementation of a comprehensive CAPA plan.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s QU failed to adequately execute its responsibilities. For example:\u003C\u002Fp>\n\n\u003Cp>A. Your QU failed to follow approved, written production and process controls. Your firm was manufacturing Multi Action Relief Drops, Polyvinyl Alcohol 0.5%, Povidone 0.6%, and Tetrahydrozoline HCl 0.05% using non-pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a preservative. When your customer requested a switch to pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you proceeded to repeat process validation without opening a change control per SOP KHIL\u002FRB\u002FQA\u002F016\u002F-R07, “Change Control.” You also failed to conduct a risk assessment of product that was in the U.S. market with non-pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>B. Your QU released drug product batches of Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops \u003Cstrong>(b)(4)\u003C\u002Fstrong> before the process validation was completed, as required in your SOP KHIL\u002FRB\u002FQA\u002F081 “Process Validation.” Your QU stated that due to a customer request they released the product for distribution before the studies were completed (21 CFR 100(a)).\u003C\u002Fp>\n\n\u003Cp>C. Your QU failed to ensure that adequate stability data supported your drug expiration dates. Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops \u003Cstrong>(b)(4)\u003C\u002Fstrong> was released with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date based on only three months of accelerated stability data. (21 CFR 211.166(b)).\u003C\u002Fp>\n\n\u003Cp>D. Your sampling plan to test for diethylene glycol (DEG) and ethylene glycol (EG) in polyethylene glycol is not representative. For example, when receiving the same vendor lot of polyethylene glycol multiple times, only the first shipment of the lot is sampled and tested for DEG and EG. Subsequent shipments with the same vendor lot are not sampled and tested for DEG and EG (21 CFR 211.84).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate for the following:\u003C\u002Fp>\n\n\u003Cp>A. You failed to review all formulations to ensure that when required, United States Pharmacopeia (USP) grade materials are used to manufacture drug products for the U.S. market and that change controls are opened when required by your procedure.\u003C\u002Fp>\n\n\u003Cp>B. Procedural updates are not sufficient to address the QU disregarding what was written in the previous version of the SOP to release product without completed process validation.\u003C\u002Fp>\n\n\u003Cp>C. A review of expiration dates and the stability data that support them was not included as part of your response.\u003C\u002Fp>\n\n\u003Cp>D. A plan for testing to verify that DEG and EG was at acceptable levels in all lots of raw materials and finished drug products was not included as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Delay in Drug Product Recall\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA held a teleconference with your firm and your U.S. Agent on October 25, 2023, to discuss our concerns regarding your sterile ophthalmic drug products. During this call, we recommended that you recall all drug products within expiry due to the insanitary conditions at your facility and other egregious violations, as described in this letter.\u003C\u002Fp>\n\n\u003Cp>Due to the potential public health risks associated with the situation at your facility, the Agency released their own announcement on October 27, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye). Despite numerous attempts by the Agency to obtain your recall decision, your firm did not initiate a recall until November 15, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fkilitch-healthcare-india-limited-issues-voluntary-nationwide-recall-various-eye-drops-potential), approximately three weeks after the initial discussion.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend production of all drugs for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive actions (CAPAs).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on October 23, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kilitch Healthcare India Limited, T T C Industrial Road, Navi Mumbai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011853060 and ATTN: Sarah Rhoades.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paresh Mehta\n\nRecipient Title\n\nManaging Director\n\nKilitch Healthcare India Limited\n\n902-B, Godrej Coliseum, Behind Everard Nagar\n\nOff. Eastern Express Highway, Nr. Priyadarshani Circle\n\nSion (E.), Mumbai 400022\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-29\n\nMarch 28, 2024\n\nDear Mr. Mehta:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kilitch Healthcare India Limited, FEI 3011853060, at R - 904 905 T T C Industrial Road,\n\nNavi Mumbai from October 12 to October 20, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nBecause your drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, your drug products are also adulterated within the meaning of section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A).\n\nWe reviewed your November 10, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nInsanitary Conditions\n\nYour drug products are adulterated under section 501(a)(2)(A) of the FD&C Act because they were prepared, packed, or held under insanitary conditions. FDA investigators observed your facility to be in a state of disrepair, poorly cleaned and maintained as evidenced by:\n\n(b)(4) residue on the (b)(4) adjacent to the HEPA filters in the ISO 5 area.\n\nMultiple barefoot employees in an ISO 8 area, without required gowning, including gloves, while handling materials being transferred into the ISO 7 manufacturing area.\n\nOperators used visibly dirty restricted access barrier system (RABS) (b)(4) for interventions on the filling line.\n\nYour response is not adequate. While you commit to replacing the (b)(4) that surround the HEPA filtration system, your response does not include an evaluation of the residue on the (b)(4) to determine its identity or investigate the source. You also commit to perform re-training of personnel for gowning requirements and implement a procedure for sterilization of RABS (b)(4), however, you do not evaluate the microbiological impact that lack of proper gowning and unclean RABS (b)(4) has on your classified areas, such as ISO 5, ISO 7, and ISO 8. The potential impact to sterile drug products produced under these insanitary conditions is also not addressed.\n\nCGMP Violations\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nPoor Practices in the Aseptic Processing Areas\n\nIn addition to the insanitary conditions described above, during the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile drug products. These poor practices included, but are not limited to:\n\nOperators performing interventions on the filling line in ISO 5 areas using a cloth to wipe the (b)(4) of the filling (b)(4) and the conveyor.\n\nOperators leaning over the filling line, including open and filled eye drop bottles, blocking unidirectional airflow.\n\nOperators in the ISO 5 area not wearing goggles and therefore had exposed skin during line set-up and aseptic processing.\n\nOperators observed placing bags of components that made contact with the walls in the ISO 7 area into the ISO 5 area without the bags being disinfected.\n\nYour response is inadequate because it does not address the lack of oversight for the operators’ aseptic behaviors and if the initial training received was sufficient. Further, these poor aseptic practices were not investigated to determine the impact to sterile drug products and aseptic processing areas.\n\nInadequate Media Fill Program\n\nYour media fills failed to accurately simulate commercial operations. Our inspection found the aseptic operations simulated during your media fills were not sufficiently representative of commercial aseptic manufacturing operations. It is your routine practice not to document interventions of the filling line in the manufacturing batch record during production. Because of this, your program lacks reliable data to determine the quantity and duration of interventions to simulate during media fills. In addition, during the inspection there were numerous interventions performed during routine manufacturing that were either not simulated as part of a media fill, or lacking in quantity and duration in the media fills compared to what was observed during production.\n\nYour response is inadequate. While you commit to document routine interventions during manufacturing, you fail to evaluate the interventions used in your media fill program and whether they represent routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity and duration of process simulation interventions should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and sterility assurance cannot be accurately assessed.\n\nInadequate Smoke Studies\n\nSmoke studies performed by your firm are not adequate to show unidirectional airflow in the aseptic processing areas. Multiple instances of turbulent airflow in critical areas of the (b)(4) filling line were noted, including above the filling (b)(4). In addition, smoke study videos did not include set-up of the aseptic processing line or interventions of the filling line that simulate actual manufacturing.\n\nIn your response you commit to repeat smoke studies with defined set-up and interventions. This is not adequate as you do not provide details such as who is performing and evaluating the smoke studies, how you will determine what interventions are included, and how you will address potential deficiencies.\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches.\n\nAlso describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nComplete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\n\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and suitability, including ergonomics for each human interaction.\n\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\n\no Reduction or elimination of aseptic manipulations and connections (e.g., replacing (b)(4) aseptic connections with (b)(4) system)\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nA plan to implement systemic remediations that address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\n\n2. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour firm failed to collect the required amount of environmental and personnel monitoring samples required by your procedures to support the manufacture of sterile drug products. During the inspection, a reconciliation of samples that should have been taken during manufacturing activities and those that were actually taken did not match. Interviews with microbiology laboratory staff and management confirmed that it is your routine practice to fabricate results for samples that were never taken or to alter results for samples that would otherwise fail to meet established specifications.\n\nBatch record information for environmental monitoring (EM) is not recorded at the time of completion. For example, a batch record was being filled out in the microbiology laboratory on October 12, 2023, for batch (b)(4) that was manufactured in March 2023, approximately six months prior to the recorded date. Data for the microbiological activity in the filtration\u002Ffilling area in the batch record was blank on October 12, 2023. This includes the air sample and non-viable particulate counting start and end times, activity done by signatures and dates, and the checked by signatures and dates. When the record was later provided on October 19, 2023, the record was filled out with times, signatures, and dates in March 2023.\n\nDuring our inspection, investigators observed multiple sample collections in the ISO 5 and ISO 7 areas, and on personnel that resulted in plate readings with numerous colony forming units (CFUs). Your firm stated that prior to the start of the inspection, where you admitted routine fabrication of environmental monitoring results, no single action limit excursion had been documented, however, FDA investigators observed the following during the inspection:\n\n15 action level excursions for ISO 5 area environmental monitoring samples\n\n13 action level excursions for personnel monitoring samples\n\n5 action level excursions for ISO 7 area environmental monitoring samples\n\nLaboratory technicians falsified this data which is critical to maintaining an ongoing state of control in your aseptic processing facility. Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nYour response states that a new checklist and procedure for oversight will be implemented. This response is not adequate as it does not address the data integrity issues that were identified by FDA. In addition, your response does not include a holistic review of data recording practices at your facility. Further, your corrective action and preventive action (CAPA) of adding a laboratory quality unit (QU) checklist for microbiologist tasks is not adequate to ensure contemporaneous completion of laboratory records.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document\n\nData Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\n3. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\n\nEnvironmental Monitoring Deficiencies\n\nYour environmental monitoring (EM) program is deficient. Locations selected for EM in critical areas such as the ISO 5 aseptic processing line, do not have scientific justification to support the chosen locations. For example, standard operating procedure (SOP) KHIL\u002FRB\u002FQC\u002F036 “Swab Testing” describes locations such as “(b)(4)” without providing details to ensure samples are taken from the same location each time. When asked to provide justification for sampling locations, no documentation was provided.\n\nAdditionally, the materials used to perform environmental and personnel monitoring are inadequate. The media used does not contain a neutralizing agent and operators were observed spraying (b)(4) near open plates. The plates themselves were observed numerous times to have desiccated media pulling away from the sides of the plates and cracking.\n\nYour response is inadequate as you do not include a risk based, scientific study to determine sampling locations for your environmental monitoring. In addition, you failed to evaluate how the growth media and plate deficiencies potentially impact your drug products and facility’s state of control for microbial contamination.\n\nFacility Maintenance Deficiencies\n\nDuring the inspection, numerous instances of your facility being in a state of disrepair or unclean were noted. This includes but is not limited to:\n\n(b)(4) surrounding the HEPA filters in the ISO 5 area were detached, creating gaps where air from the ISO 7 area could flow into the ISO 5 area.\n\nHose connected to a leaking purified water use point was submerged in a bucket of stagnant water.\n\nPeeling paint, stains, and residue on the ceiling of the (b)(4) room.\n\nYour response is inadequate as you failed to consider that persistently deficient environmental controls (e.g., poor design of processing lines, lack of data integrity, and insufficient environmental monitoring) provide a fundamental lack of meaningful retrospective data to support sterility assurance.\n\nA vigilant ongoing EM program, and supporting laboratory, are essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\n\nIn response to this letter, provide:\n\nAn independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling frequencies, investigating deviations, and trend analysis. Also ensure the implementation of a comprehensive CAPA plan.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm’s QU failed to adequately execute its responsibilities. For example:\n\nA. Your QU failed to follow approved, written production and process controls. Your firm was manufacturing Multi Action Relief Drops, Polyvinyl Alcohol 0.5%, Povidone 0.6%, and Tetrahydrozoline HCl 0.05% using non-pharmaceutical grade (b)(4) as a preservative. When your customer requested a switch to pharmaceutical grade (b)(4), you proceeded to repeat process validation without opening a change control per SOP KHIL\u002FRB\u002FQA\u002F016\u002F-R07, “Change Control.” You also failed to conduct a risk assessment of product that was in the U.S. market with non-pharmaceutical grade (b)(4).\n\nB. Your QU released drug product batches of Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops (b)(4) before the process validation was completed, as required in your SOP KHIL\u002FRB\u002FQA\u002F081 “Process Validation.” Your QU stated that due to a customer request they released the product for distribution before the studies were completed (21 CFR 100(a)).\n\nC. Your QU failed to ensure that adequate stability data supported your drug expiration dates. Equate Hydration Polyethylene Glycol 400 and Propylene Glycol Eye Drops (b)(4) was released with a (b)(4) expiration date based on only three months of accelerated stability data. (21 CFR 211.166(b)).\n\nD. Your sampling plan to test for diethylene glycol (DEG) and ethylene glycol (EG) in polyethylene glycol is not representative. For example, when receiving the same vendor lot of polyethylene glycol multiple times, only the first shipment of the lot is sampled and tested for DEG and EG. Subsequent shipments with the same vendor lot are not sampled and tested for DEG and EG (21 CFR 211.84).\n\nYour response is inadequate for the following:\n\nA. You failed to review all formulations to ensure that when required, United States Pharmacopeia (USP) grade materials are used to manufacture drug products for the U.S. market and that change controls are opened when required by your procedure.\n\nB. Procedural updates are not sufficient to address the QU disregarding what was written in the previous version of the SOP to release product without completed process validation.\n\nC. A review of expiration dates and the stability data that support them was not included as part of your response.\n\nD. A plan for testing to verify that DEG and EG was at acceptable levels in all lots of raw materials and finished drug products was not included as part of your corrective action plan.\n\nIn response to this letter, provide the following:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nDelay in Drug Product Recall\n\nFDA held a teleconference with your firm and your U.S. Agent on October 25, 2023, to discuss our concerns regarding your sterile ophthalmic drug products. During this call, we recommended that you recall all drug products within expiry due to the insanitary conditions at your facility and other egregious violations, as described in this letter.\n\nDue to the potential public health risks associated with the situation at your facility, the Agency released their own announcement on October 27, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye). Despite numerous attempts by the Agency to obtain your recall decision, your firm did not initiate a recall until November 15, 2023 (https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fkilitch-healthcare-india-limited-issues-voluntary-nationwide-recall-various-eye-drops-potential), approximately three weeks after the initial discussion.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend production of all drugs for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive actions (CAPAs).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on October 23, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Kilitch Healthcare India Limited, T T C Industrial Road, Navi Mumbai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011853060 and ATTN: Sarah Rhoades.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n___________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Kilitch Healthcare India Limited","kilitch-healthcare-india-limited-672956-03282024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkilitch-healthcare-india-limited-672956-03282024","2026-10-26T08:09:08.906666+00:00","2024-04-09","672956","Drugs","Mr. Paresh Mehta","2026-08-20T00:11:39.349+00:00","VIA Electronic Mail","2024-03-28",{"id":81,"raw":82,"subject":87,"body_html":88,"body_text":89,"firm_name":90,"letter_id":91,"created_at":92,"fei_number":20,"letter_url":93,"updated_at":94,"action_type":23,"case_status":49,"posted_date":95,"marcs_cms_no":96,"product_type":75,"closeout_date":20,"issuing_office":86,"recipient_name":97,"body_fetched_at":98,"delivery_method":78,"recipient_title":20,"reference_number":20,"action_taken_date":99,"medical_device_id":20,"response_letter_date":20},2233,[83,84,85,86,87,13,13,13],"\u003Ctime datetime=\"2023-01-31T05:00:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-27T05:00:00Z\">01\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkobayashi-healthcare-international-inc-637313-01272023\">Kobayashi Healthcare International, Inc.\u003C\u002Fa>","Office of Pharmaceutical Quality","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Norikazu Toyoda\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kobayashi Healthcare International, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>245 Kraft Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dalton\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30721-1502\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 27, 2023\u003C\u002Fp>\n\n\u003Cp>Case #637313\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Toyoda:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kobayashi America Manufacturing, LLC, FEI 3003079019, at 245 Kraft Drive, Dalton, Georgia, from May 23 to 27, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352 (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 21, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm released over-the-counter (OTC) drug products, Zim’s Max Freeze Gel, Zim’s Max Freeze Roll-on, and Zim’s Max Freeze Liquid, without testing batches for microbiological quality. For example, Zim’s Max Freeze Roll-on, lot B87695, was released by your quality unit (QU) on January 20, 2022, without undergoing microbiological testing. Your Quality Assurance Director informed our investigators, during the inspection, that microbiological testing is not a part of finished product release testing.\u003C\u002Fp>\n\n\u003Cp>Microbiological testing is essential to ensure each batch of your finished drug products conform to appropriate microbiological specifications. Testing prior to release and throughout the drug product’s life cycle is imperative to accomplish this standard.\u003C\u002Fp>\n\n\u003Cp>In your response, you claimed there was no danger of objectionable microorganisms in the finished drug product as the percentages of alcohol in the products do not support microbial growth or survival. You also indicated that the finished drug products currently on the market are safe.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. It is well established that certain microorganisms are known to survive and thrive in alcohol. Additionally, you did not provide any retrospective testing to support the safety of your drug products currently on the market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of microbiological specifications (i.e., total counts, objectionable microorganisms), including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent assessment of the microbiological test methods you plan to use to ensure that they are adequately validated and\u002For verified to be suitable for their intended purposes.\u003C\u002Fli>\n\t\u003Cli>Appropriate scientific studies to evaluate antimicrobial effectiveness testing (AET) for your aqueous multi-dose drug products. AET by USP &lt;51&gt; testing should be performed at a range of preservative concentrations and should be inclusive of concentrations at or below that listed in the formulation for each drug product. In addition to initial USP &lt;51&gt; studies on your formulations, one of the primary batches of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the end of the proposed shelf life. The drug product specification should include a test for preservative content, and this attribute should be tested in all stability studies.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked an adequate QU. Your QU failed to establish and follow procedures\u003Cbr>\ndescribing its roles, responsibilities, and authorities. Furthermore, your QU’s oversight\u003Cbr>\nof drug manufacturing operations was inadequate. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Production and control records from your OTC drug product contract manufacturer were not reviewed or approved prior to release and distribution.\u003C\u002Fli>\n\t\u003Cli>Zim’s Max Freeze S, lot B77086 was intended for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but you relabeled the lot for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> without review and approval of manufacturing, packaging, and testing records to assure it met \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards.\u003C\u002Fli>\n\t\u003Cli>There was a failure to establish adequate procedures for maintaining and investigating customer complaints.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you stated that your batch record review and complaint investigation deficiencies were due to the lack of QU documentation and sufficient detail.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response failed to provide an adequate retrospective review of production records to ensure all batches currently on the market were manufactured to your established specifications.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Also describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A retrospective review of each batch currently on the market and its related information to determine if all established specifications were met before the QU disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality&nbsp;\u003C\u002Fem>\u003Cem>Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an external analgesic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the product’s labeling, including the website listed on product label, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; “BACK, Hip, Neck, Shoulder, Knee . . . \u003Cem>Drug Facts\u003C\u002Fem> . . . \u003Cem>Uses\u003C\u002Fem> . . . For the temporary relief of pain” [from your product’s outer carton]\u003C\u002Fp>\n\n\u003Cp>&nbsp; “Zim’s Max Freeze Hydro Cooling Pain Relief Patches provide immediate cooling relief . . . ready to use anywhere and anytime you need deep penetrating pain relief. Gently adheres to back, hips, neck, shoulders, and knees. . . . targeted pain relief that penetrates to the source of your discomfort.” [amazon.com\u002FZims-Max-Lidocaine-Cooling-P251220\u002Fdp\u002FBOB33B3ZKM?ref_=ast+sto_dp] [from the website of one of your retailers, Amazon.com; your website “WHERE TO BUY” provides a direct link to this and other retailers].\u003C\u002Fp>\n\n\u003Cp>“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under section 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>This final administrative order addresses counterirritants, analgesic\u002Fanesthetics, and antipruritics, and it identifies active ingredients, dosage strengths, and indications for use corresponding to each of these categories of external analgesic drug products. Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” product does not conform to the conditions of use specified in the final administrative order, as described below.\u003C\u002Fp>\n\n\u003Cp>Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is labeled for use as a counterirritant external analgesic drug product because it includes claims related to the relief of pain in muscles and joints. For example, your product is labeled with the indication “For the temporary relief of pain,” and it identifies the back, hip, neck, shoulder, and knee. The labeling thus conveys that the product is intended for use in the temporary relief of pain in muscles and joints, including the back, hip, neck, shoulder, and knee. Further, the outer carton describes “deep penetrating” and “cooling” relief, and the product’s name includes the term “cooling.” The final administrative order requires the statement of indication for counterirritant external analgesic drug products include the phrase, “For the temporary relief of minor aches and pains of muscles and joints,” and it allows certain other statements including “penetrating pain relief” and “cooling pain relief.” Other categories of products addressed in the final administrative order, including analgesic and anesthetic drug products, are not permitted to include such an indication or statements in their labeling.\u003C\u002Fp>\n\n\u003Cp>However, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not formulated as a counterirritant external analgesic drug product consistent with the final administrative order. The product is labeled to contain the active ingredients lidocaine at a dosage strength of 4% and menthol at a dosage strength of 1%. Lidocaine is not included as an active ingredient in the final administrative order for an external analgesic counterirritant drug product. Further, the final administrative order includes menthol in a dosage range of 1.25 – 16% for counterirritant external analgesic drug products. Therefore, even if menthol was the sole active ingredient, at a dosage of 1%, it falls below the allowable dosage strength range of 1.25 – 16% for menthol used in counterirritant external analgesic drug products.\u003C\u002Fp>\n\n\u003Cp>We note that, pursuant to the final administrative order, analgesic and anesthetic drug products may contain lidocaine at a dosage strength of 0.5% to 4% and menthol at a dosage strength of 0.1% to 1%. However, as noted above, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not labeled with statements that the final administrative order permits for analgesic or anesthetic drug products (not counterirritants).\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (\u003Cstrong>Case #637313\u003C\u002Fstrong>). Please electronically submit your signed reply on your firm’s letterhead to Ronda R. Loyd-Jones, Director, Compliance Branch, at email to: Ronda.Loyd-Jones@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nDivision Director\u003Cbr>\nOffice of Pharmaceutical Quality Operation\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>cc: Via Electronic Mail\u003Cbr>\nMr. Hajime Furuie\u003Cbr>\nQuality Assurance\u002FRegulatory Affairs Director\u003Cbr>\nKobayashi Healthcare International, Inc.\u003Cbr>\n245 Kraft Drive\u003Cbr>\nDalton, GA 30721\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Norikazu Toyoda\n\nRecipient Title\n\nPresident and CEO\n\nKobayashi Healthcare International, Inc.\n\n245 Kraft Dr.\n\nDalton, GA 30721-1502\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality\n\nUnited States\n\nJanuary 27, 2023\n\nCase #637313\n\nWARNING LETTER\n\nDear Mr. Toyoda:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Kobayashi America Manufacturing, LLC, FEI 3003079019, at 245 Kraft Drive, Dalton, Georgia, from May 23 to 27, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352 (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your June 21, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released over-the-counter (OTC) drug products, Zim’s Max Freeze Gel, Zim’s Max Freeze Roll-on, and Zim’s Max Freeze Liquid, without testing batches for microbiological quality. For example, Zim’s Max Freeze Roll-on, lot B87695, was released by your quality unit (QU) on January 20, 2022, without undergoing microbiological testing. Your Quality Assurance Director informed our investigators, during the inspection, that microbiological testing is not a part of finished product release testing.\n\nMicrobiological testing is essential to ensure each batch of your finished drug products conform to appropriate microbiological specifications. Testing prior to release and throughout the drug product’s life cycle is imperative to accomplish this standard.\n\nIn your response, you claimed there was no danger of objectionable microorganisms in the finished drug product as the percentages of alcohol in the products do not support microbial growth or survival. You also indicated that the finished drug products currently on the market are safe.\n\nYour response is inadequate. You did not provide an appropriate scientific basis to support that your finished drug products are free from microbial growth or survival. It is well established that certain microorganisms are known to survive and thrive in alcohol. Additionally, you did not provide any retrospective testing to support the safety of your drug products currently on the market.\n\nIn response to this letter, provide:\n\nA list of microbiological specifications (i.e., total counts, objectionable microorganisms), including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nAn independent assessment of the microbiological test methods you plan to use to ensure that they are adequately validated and\u002For verified to be suitable for their intended purposes.\n\nAppropriate scientific studies to evaluate antimicrobial effectiveness testing (AET) for your aqueous multi-dose drug products. AET by USP \u003C51> testing should be performed at a range of preservative concentrations and should be inclusive of concentrations at or below that listed in the formulation for each drug product. In addition to initial USP \u003C51> studies on your formulations, one of the primary batches of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the end of the proposed shelf life. The drug product specification should include a test for preservative content, and this attribute should be tested in all stability studies.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm lacked an adequate QU. Your QU failed to establish and follow procedures\n\ndescribing its roles, responsibilities, and authorities. Furthermore, your QU’s oversight\n\nof drug manufacturing operations was inadequate. For example:\n\nProduction and control records from your OTC drug product contract manufacturer were not reviewed or approved prior to release and distribution.\n\nZim’s Max Freeze S, lot B77086 was intended for the (b)(4), but you relabeled the lot for the (b)(4) without review and approval of manufacturing, packaging, and testing records to assure it met (b)(4) standards.\n\nThere was a failure to establish adequate procedures for maintaining and investigating customer complaints.\n\nIn your response, you stated that your batch record review and complaint investigation deficiencies were due to the lack of QU documentation and sufficient detail.\n\nYour response is inadequate. Your response failed to provide an adequate retrospective review of production records to ensure all batches currently on the market were manufactured to your established specifications.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA retrospective review of each batch currently on the market and its related information to determine if all established specifications were met before the QU disposition decision.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\n\nConsultant Recommended\n\nWe strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUnapproved New Drug and Misbranding Violations\n\n“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an external analgesic.\n\nExamples of claims from the product’s labeling, including the website listed on product label, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“BACK, Hip, Neck, Shoulder, Knee . . . Drug Facts . . . Uses . . . For the temporary relief of pain” [from your product’s outer carton]\n\n“Zim’s Max Freeze Hydro Cooling Pain Relief Patches provide immediate cooling relief . . . ready to use anywhere and anytime you need deep penetrating pain relief. Gently adheres to back, hips, neck, shoulders, and knees. . . . targeted pain relief that penetrates to the source of your discomfort.” [amazon.com\u002FZims-Max-Lidocaine-Cooling-P251220\u002Fdp\u002FBOB33B3ZKM?ref_=ast+sto_dp] [from the website of one of your retailers, Amazon.com; your website “WHERE TO BUY” provides a direct link to this and other retailers].\n\n“ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under section 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\n\nThis final administrative order addresses counterirritants, analgesic\u002Fanesthetics, and antipruritics, and it identifies active ingredients, dosage strengths, and indications for use corresponding to each of these categories of external analgesic drug products. Your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH,” product does not conform to the conditions of use specified in the final administrative order, as described below.\n\nYour “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is labeled for use as a counterirritant external analgesic drug product because it includes claims related to the relief of pain in muscles and joints. For example, your product is labeled with the indication “For the temporary relief of pain,” and it identifies the back, hip, neck, shoulder, and knee. The labeling thus conveys that the product is intended for use in the temporary relief of pain in muscles and joints, including the back, hip, neck, shoulder, and knee. Further, the outer carton describes “deep penetrating” and “cooling” relief, and the product’s name includes the term “cooling.” The final administrative order requires the statement of indication for counterirritant external analgesic drug products include the phrase, “For the temporary relief of minor aches and pains of muscles and joints,” and it allows certain other statements including “penetrating pain relief” and “cooling pain relief.” Other categories of products addressed in the final administrative order, including analgesic and anesthetic drug products, are not permitted to include such an indication or statements in their labeling.\n\nHowever, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not formulated as a counterirritant external analgesic drug product consistent with the final administrative order. The product is labeled to contain the active ingredients lidocaine at a dosage strength of 4% and menthol at a dosage strength of 1%. Lidocaine is not included as an active ingredient in the final administrative order for an external analgesic counterirritant drug product. Further, the final administrative order includes menthol in a dosage range of 1.25 – 16% for counterirritant external analgesic drug products. Therefore, even if menthol was the sole active ingredient, at a dosage of 1%, it falls below the allowable dosage strength range of 1.25 – 16% for menthol used in counterirritant external analgesic drug products.\n\nWe note that, pursuant to the final administrative order, analgesic and anesthetic drug products may contain lidocaine at a dosage strength of 0.5% to 4% and menthol at a dosage strength of 0.1% to 1%. However, as noted above, your “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is not labeled with statements that the final administrative order permits for analgesic or anesthetic drug products (not counterirritants).\n\nFDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because “ZIM’S HYDRO COOLING PAIN RELIEF PATCH” is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (Case #637313). Please electronically submit your signed reply on your firm’s letterhead to Ronda R. Loyd-Jones, Director, Compliance Branch, at email to: Ronda.Loyd-Jones@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nDivision Director\n\nOffice of Pharmaceutical Quality Operation\n\nDivision II\n\ncc: Via Electronic Mail\n\nMr. Hajime Furuie\n\nQuality Assurance\u002FRegulatory Affairs Director\n\nKobayashi Healthcare International, Inc.\n\n245 Kraft Drive\n\nDalton, GA 30721","Kobayashi Healthcare International, Inc.","kobayashi-healthcare-international-inc-637313-01272023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkobayashi-healthcare-international-inc-637313-01272023","2026-10-26T08:09:09.897874+00:00","2023-01-31","637313","Mr. Norikazu Toyoda","2026-08-20T01:16:59.473+00:00","2023-01-27",4,{"510k":102,"classification":103,"enforcement":104,"event":105,"event_backfill":106,"pma":107,"warning_letter":108},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]